Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia

Blood

Volumn 128, Issue 7, 2016, Pages 911-922

  Irving, Julie A E ^a   Enshaei, Amir ^a   Parker, Catriona A ^b,c   Sutton, Rosemary ^d   Kuiper, Roland P ^e   Erhorn, Amy ^a   Minto, Lynne ^a   Venn, Nicola C ^d   Law, Tamara ^d   Yu, Jiangyan ^e   Schwab, Claire ^a   Davies, Rosanna ^a   Matheson, Elizabeth ^a   Davies, Alysia ^a   Sonneveld, Edwin ^f   Den Boer, Monique L ^f,g   Love, Sharon B ^h   Harrison, Christine J ^a   Hoogerbrugge, Peter M ^f,i   Revesz, Tamas ^j   Saha, Vaskar ^b,c,k   Moorman, Anthony V ^a   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f DCOG Dutch Childhood Oncology Group   (Netherlands)

^g SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ the Netherlands The Innovative Therapies for Children with Cancer Consortium   (Netherlands)

^j UNIVERSITY OF ADELAIDE   (Australia)

^k TATA MEDICAL CENTER   (India)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IDARUBICIN; MITOXANTRONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; CYTOGENETICS; GENE; GENE DELETION; GENE MUTATION; GENETIC ALGORITHM; GENETIC RISK; HAPLOIDY; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NRAS GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEQUENCE ANALYSIS; SURVIVAL RATE; ADOLESCENT; CHROMOSOME ANALYSIS; COHORT ANALYSIS; DEMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; INFANT; MALE; MUTATION; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; COHORT STUDIES; CYTOGENETIC ANALYSIS; DEMOGRAPHY; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MALE; MUTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 84984656920     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-704973     Document Type: Article

References (36)

1. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26(3):123-135.
2. Moorman AV, Enshaei A, Schwab C, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood. 2014;124(9): 1434-1444.
3. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11(5):429-438.
4. Moorman AV, Robinson H, Schwab C, et al. Riskdirected treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol. 2013;31(27):3389-3396.
5. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013; 14(6):e205-e217.
6. Wehrli LA, Braun J, Buetti LN, et al. Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2009;189(1):29-36.
7. Vora AJ, Potter AM, Anderson LM, Lilleyman JS. Frequency and importance of change in blast cell karyotype in relapsing childhood lymphoblastic leukemia. Pediatr Hematol Oncol. 1994;11(4): 379-386.
8. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008; 322(5906):1377-1380.
9. Yang JJ, Bhojwani D, Yang W, et al. Genomewide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008; 112(10):4178-4183.
10. Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23): 3420-3430.
11. Aries IM, van den Dungen RE, Koudijs MJ, et al. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica. 2015; 100(4):e132-e136.
12. Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29(23):3185-3193.
13. Hogan LE, Meyer JA, Yang J, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood. 2011;118(19):5218-5226.
14. Krentz S, Hof J, Mendioroz A, et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. 2013;27(2):295-304.
15. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010; 376(9757):2009-2017.
16. Krishnan S, Wade R, Moorman AV, et al. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia. 2010;24(2):450-459.
17. Masurekar AN, Parker CA, Shanyinde M, et al. Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia- prospective open cohort analyses of the ALLR3 trial. PLoS One. 2014;9(10):e108107.
18. van der Velden VH, Cazzaniga G, Schrauder A, et al; European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4): 604-611.
19. Schwab CJ, Jones LR, Morrison H, et al. Evaluation of multiplex ligation-dependent probe amplification (MLPA) as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukaemia. Genes Chromosomes Cancer. 2010;49(12):1104-1113.
20. Schwab CJ, Chilton L, Morrison H, et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica. 2013;98(7):1081-1088.
21. Rand V, Parker H, Russell LJ, et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2011;117(25):6848-6855.
22. Case M, Matheson E, Minto L, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008;68(16):6803-6809.
23. Wiemels JL, Zhang Y, Chang J, et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia. 2005;19(3): 415-419.
24. Malinowska-Ozdowy K, Frech C, Schonegger A, et al. KRAS and CREBBP mutations: a relapselinked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia. 2015;29(8):1656-1667.
25. Jeha S, Pei D, Raimondi SC, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia. 2009;23(8): 1406-1409.
26. Russell LJ, Enshaei A, Jones L, et al. IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. J Clin Oncol. 2014;32(14):1453-1462.
27. Irving JA, Minto L, Bailey S, Hall AG. Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Res. 2005;65(21): 9712-9718.
28. Zaliova M, Zimmermannova O, Dorge P, et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia. 2014;28(1):182-185.
29. Palmi C, Valsecchi MG, Longinotti G, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphianegative B-cell precursor acute lymphoblastic leukemia? Haematologica. 2013;98(8): 1226-1231.
30. Enshaei A, Schwab CJ, Konn ZJ, et al. Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. Leukemia. 2013;27(11): 2256-2259.
31. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3): 242-252.
32. Waanders E, Scheijen B, van der Meer LT, et al. The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet. 2012;8(2):e1002533.
33. van Galen JC, Kuiper RP, van Emst L, et al. BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood. 2010; 115(23):4810-4819.
34. Schmidt S, Irving JA, Minto L, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J. 2006;20(14): 2600-2602.
35. Donner KM, Hiltunen TP, Janne OA, Sane T, Kontula K. Generalized glucocorticoid resistance caused by a novel two-nucleotide deletion in the hormone-binding domain of the glucocorticoid receptor gene NR3C1. Eur J Endocrinol. 2012; 168(1):K9-K18.
36. Bokemeyer A, Eckert C, Meyr F, et al. Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia. Haematologica. 2014; 99(4):706-714.